Cabaletta reports Q2 2026 results, reaffirms mid-2027 myositis data and 2H27 BLA plan
The company also plans to start a registrational systemic sclerosis-ILD study in 4Q26 and said cash on hand funds operations into mid-2027.
SEC filing
Latest
1 story